NCT02153476View on ClinicalTrials.gov

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Symptomatic Focal Vitreomacular Adhesion
Interventions
DRUG

2.0mg of ALG-1001

DRUG

Balanced Salt Solution

Trial Locations (5)

33880

Center for Retinal and Macular Disease, Winter Haven

77030

Retina Consultants Houston, Houston

78705

Austin Retina Associates, Austin

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

93103

California Retina Consultants, Santa Barbara

Sponsors
All Listed Sponsors
lead

Allegro Ophthalmics, LLC

INDUSTRY

NCT02153476 - A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion | Biotech Hunter | Biotech Hunter